KRAS and neoplasm: Importantly, BRMS1 inhibits these cellular phenotypes even in the context of oncogenic K-ras expression and loss of p53 tumor suppressor activity, suggesting that intratumoral BRMS1 expression needs to be down-regulated in NSCLC to fulfill cellular phenotypes known to promote metastasis.